The GIST of targeted therapy for malignant melanoma.
The GIST of targeted therapy for malignant melanoma.
复制标题
DOI：
10.1245/s10434-013-3373-z
复制
发表时间：
2014-06
影响因子：
3.7
通讯作者：
Ariyan CE
中科院分区：
文献类型：
--
作者：
Bello DM;Dematteo RP;Ariyan CE
酪氨酸激酶抑制剂伊马替尼在KIT突变的胃肠道间质瘤（GIST）中的高应答率导致了癌症治疗的范式转变。以平行的方式，黑色素瘤领域正在随着靶向治疗的利用而转移，以治疗BRAF突变的黑色素瘤。我们回顾了PubMed上关于胃肠道间质瘤和黑色素瘤的已发表文献，重点关注过去和当前的临床试验。这些数据集中在伊马替尼、维罗非尼和最近的达拉非尼上，靶向KIT和BRAF突变及其在GIST和黑色素瘤中的结局。BRAFV 600 E黑色素瘤突变，如GIST中的KIT外显子11突变，对治疗的反应最高。在GIST中抑制KIT的高反应率在KIT突变的黑色素瘤中没有重现。GIST中，BRAF抑制剂的靶向药物耐药中位时间约为7个月，伊马替尼为2年。在GIST中，继发性突变的发展导致耐药性;然而，在黑色素瘤中没有发现类似的看门突变。虽然手术仍然是早期GIST和黑色素瘤治疗的重要组成部分，但外科医生需要继续确定转移性疾病的阈值和手术时机，并改进靶向治疗。联合治疗策略可能会导致更成功的临床结果在未来的黑色素瘤的管理。
The high response rates to the tyrosine kinase inhibitor imatinib in KIT-mutated gastrointestinal stromal tumors (GIST) has led to a paradigm shift in cancer treatment. In a parallel fashion, the field of melanoma is shifting with the utilization of targeted therapy to treat BRAF-mutated melanoma. We reviewed published literature in PubMed on GIST and melanoma, with a focus on both past and current clinical trials. The data presented centers on imatinib, vemurafenib, and most recently dabrafenib, targeting KIT and BRAF mutations and their outcomes in GIST and melanoma. The BRAFV600E melanoma mutation, like the KIT exon 11 mutation in GIST, has the highest response to therapy. High response rates with inhibition of KIT in GIST have not been recapitulated in KIT-mutated melanoma. Median time to resistance to targeted agents occurs in ~7 months with BRAF inhibitors and 2 years for imatinib in GIST. In GIST, the development of secondary mutations leads to resistance; however, there have been no similar gatekeeper mutations found in melanoma. Although surgery remains an important component of the treatment of early GIST and melanoma, surgeons will need to continue to define the thresholds and timing for operation in the setting of metastatic disease with improved targeted therapies. Combination treatment strategies may result in more successful clinical outcomes in the management of melanoma in the future.
登录
查看更多内容
影响因子：
9
作者：
DeMatteo RP;Ballman KV;Antonescu CR;Corless C;Kolesnikova V;von Mehren M;McCarter MD;Norton J;Maki RG;Pisters PW;Demetri GD;Brennan MF;Owzar K;American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology
通讯作者：
American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology
影响因子：
6.2
作者：
DeMatteo, Ronald P.;Gold, Jason S.;Antonescu, Cristina R.
通讯作者：
Antonescu, Cristina R.
影响因子：
14.9
作者：
Forbes SA;Bindal N;Bamford S;Cole C;Kok CY;Beare D;Jia M;Shepherd R;Leung K;Menzies A;Teague JW;Campbell PJ;Stratton MR;Futreal PA
通讯作者：
Futreal PA
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
DOI：
10.1056/nejmoa1002011
发表时间：
2010-08-26
期刊：
The New England journal of medicine
影响因子：
--
作者：
Flaherty KT;Puzanov I;Kim KB;Ribas A;McArthur GA;Sosman JA;O'Dwyer PJ;Lee RJ;Grippo JF;Nolop K;Chapman PB
通讯作者：
Chapman PB